BR9915421A - Processo para a fabricação de sais alcalinos levemente solúveis ou menos solúveis de heterociclos de sulfinila substituìda, forma de dosagem farmacêutica, uso da mesma, método de tratamento de doenças gastrointestinais, e, processo para a fabricação de uma forma de dosagem farmacêutica. - Google Patents

Processo para a fabricação de sais alcalinos levemente solúveis ou menos solúveis de heterociclos de sulfinila substituìda, forma de dosagem farmacêutica, uso da mesma, método de tratamento de doenças gastrointestinais, e, processo para a fabricação de uma forma de dosagem farmacêutica.

Info

Publication number
BR9915421A
BR9915421A BR9915421-8A BR9915421A BR9915421A BR 9915421 A BR9915421 A BR 9915421A BR 9915421 A BR9915421 A BR 9915421A BR 9915421 A BR9915421 A BR 9915421A
Authority
BR
Brazil
Prior art keywords
manufacture
pharmaceutical dosage
dosage form
substituted sulfinyl
substituted
Prior art date
Application number
BR9915421-8A
Other languages
English (en)
Inventor
Magnus Erickson
Anders Gustavsson
Lars Josefsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9915421(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9803952A external-priority patent/SE9803952D0/xx
Priority claimed from SE9803953A external-priority patent/SE9803953D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR9915421A publication Critical patent/BR9915421A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSO PARA A FABRICAçãO DE SAIS ALCALINOS LEVEMENTE SOLúVEIS OU MENOS SOLúVEIS DE HETEROCICLOS DE SULFINILA SUBSTITUìDA, FORMA DE DOSAGEM FARMACêUTICA, USO DA MESMA, MéTODO DE TRATAMENTO DE DOENçAS GASTROINTESTINAIS, E, PROCESSO PARA A FABRICAçãO DE UMA FORMA DE DOSAGEM FARMACêUTICA" Processo para a fabricação de sais alcalinos levemente solúveis, ou menos solúveis, de heterociclos de sulfinila substituídos contendo uma porção de imidazol com a fórmula (I), preferivelmente sais alcalinos de um composto inibidor de bomba de próton, em que o processo compreende a etapa de reagir o heterociclo de sulfinila substituído da fórmula (I) por uma fonte do cátion na presença de uma base, caracterizado por uma etapa de lavagem em que o sal alcalino preparado do composto de sulfinila substituída é lavado com uma mistura de solvente aquoso básico. A substância medicamentosa a granel, obtida, resultando em um produto a granel que em uma suspensão aquosa do heterociclo de sulfinila substituído tem um pH não significativamente inferior do que aquele de uma solução de água saturada do preparado composto puro. alternativamente, o processo para fabricação de uma forma de dosagem farmacêutica compreendendo a substância ativa deve ser ajustado. Por exemplo, o pH de uma suspensão aquosa da substância ativa é ajustado a um pH não significativamente inferior do que aquele de uma solução de água saturada do composto puro. Os processos são preferivelmente úteis na fabricação de sal de magnésio de omeprazol ou sal de magnésio de um de seus enantiómeros singulares usados nas formas de dosagens farmacêuticas.
BR9915421-8A 1998-11-18 1999-11-15 Processo para a fabricação de sais alcalinos levemente solúveis ou menos solúveis de heterociclos de sulfinila substituìda, forma de dosagem farmacêutica, uso da mesma, método de tratamento de doenças gastrointestinais, e, processo para a fabricação de uma forma de dosagem farmacêutica. BR9915421A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803952A SE9803952D0 (sv) 1998-11-18 1998-11-18 Pharmaceutical formulation
SE9803953A SE9803953D0 (sv) 1998-11-18 1998-11-18 Improved chemical process
PCT/SE1999/002093 WO2000028975A2 (en) 1998-11-18 1999-11-15 Improved chemical process and pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BR9915421A true BR9915421A (pt) 2001-08-07

Family

ID=26663439

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915421-8A BR9915421A (pt) 1998-11-18 1999-11-15 Processo para a fabricação de sais alcalinos levemente solúveis ou menos solúveis de heterociclos de sulfinila substituìda, forma de dosagem farmacêutica, uso da mesma, método de tratamento de doenças gastrointestinais, e, processo para a fabricação de uma forma de dosagem farmacêutica.

Country Status (18)

Country Link
US (1) US6403616B1 (pt)
EP (1) EP1131316B1 (pt)
JP (1) JP4610086B2 (pt)
KR (1) KR100619200B1 (pt)
CN (1) CN100503598C (pt)
AT (1) ATE271556T1 (pt)
AU (1) AU770633B2 (pt)
BR (1) BR9915421A (pt)
CA (1) CA2347981C (pt)
DE (1) DE69918854T2 (pt)
DK (1) DK1131316T3 (pt)
ES (1) ES2222754T3 (pt)
HK (1) HK1038920B (pt)
IL (2) IL142629A0 (pt)
NO (1) NO321275B1 (pt)
NZ (1) NZ511169A (pt)
PT (1) PT1131316E (pt)
WO (1) WO2000028975A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8779175B2 (en) * 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2708124B1 (en) 2011-11-10 2018-03-21 Rotam Agrochem International Co., Ltd Herbicidal composition and method of using the same
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
TNSN95062A1 (fr) 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
AUPN846496A0 (en) * 1996-03-05 1996-03-28 Research Laboratories Of Australia Pty Ltd Electronic printing for display technology
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
JP2002509604A (ja) * 1996-05-17 2002-03-26 フォームファクター,インコーポレイテッド マイクロエレクトロニクス相互接続要素のための接触チップ構造及びその製造方法
CN1128997C (zh) * 2001-01-04 2003-11-26 中国科学院南京土壤研究所 一种吸力平板的制作方法

Also Published As

Publication number Publication date
NO20012427D0 (no) 2001-05-16
PT1131316E (pt) 2004-10-29
ATE271556T1 (de) 2004-08-15
IL142629A0 (en) 2002-03-10
IL142629A (en) 2007-12-03
NZ511169A (en) 2003-06-30
WO2000028975A2 (en) 2000-05-25
HK1038920B (zh) 2005-03-11
KR100619200B1 (ko) 2006-09-05
ES2222754T3 (es) 2005-02-01
NO321275B1 (no) 2006-04-10
JP4610086B2 (ja) 2011-01-12
NO20012427L (no) 2001-07-09
AU770633B2 (en) 2004-02-26
DE69918854D1 (de) 2004-08-26
US6403616B1 (en) 2002-06-11
DK1131316T3 (da) 2004-09-27
KR20010089474A (ko) 2001-10-06
EP1131316B1 (en) 2004-07-21
HK1038920A1 (en) 2002-04-04
CN1326455A (zh) 2001-12-12
CA2347981C (en) 2010-05-04
DE69918854T2 (de) 2005-07-21
EP1131316A2 (en) 2001-09-12
CA2347981A1 (en) 2000-05-25
AU1901700A (en) 2000-06-05
JP2002529497A (ja) 2002-09-10
WO2000028975A3 (en) 2000-08-10
CN100503598C (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
BR9915421A (pt) Processo para a fabricação de sais alcalinos levemente solúveis ou menos solúveis de heterociclos de sulfinila substituìda, forma de dosagem farmacêutica, uso da mesma, método de tratamento de doenças gastrointestinais, e, processo para a fabricação de uma forma de dosagem farmacêutica.
CA2140347A1 (en) Injection and injection kit containing omeprazole and its analogs
RU95104936A (ru) Препарат для инъекций и набор для инъекций, содержащие омепразол и его аналоги
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
TR200401142T4 (tr) Glükagon-benzeri peptid bileşiklerinin çözündürülmesi için işlem.
DE60234870D1 (de) Herstellung von bisphosphonsaüren und salzen davon
YU99291A (sh) Postupak za sintezu omeprazola
FI95773B (fi) Menetelmä vesipitoisen, N-(3,4-dimetoksikinnamoyyli)antraniilihappoa sisältävän farmaseuttisen koostumuksen valmistamiseksi
SK285105B6 (sk) Dihydrát pantoprazolu horečnatého, farmaceutický prostriedok s jeho obsahom a jeho použitie
DE60036924D1 (de) 5-ht1f agonisten
ES549515A0 (es) Procedimiento para el tratamiento ulterior de ropa lavada
SE9403831L (sv) Lagringsstabil vattenlösning för infusion av trombininhibitorer
JPS56139414A (en) Stabilizing method of aqueous solution
BR9907166A (pt) Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina
KR890017259A (ko) 모액으로부터의 항생물질 회수방법 및 그의 약학적으로 허용할 수 있는 신규한 염
US2174009A (en) Therapeutic preparation
JPS6153267A (ja) 酸化および湿気に抵抗性のプロカテロ−ル誘導体およびその製法
BR0200291A (pt) Composição farmacêutica lìquida para o uso no tratamento de doenças ósseas, processo para preparar a mesma e processo para tratamento de uma doença óssea
US3068262A (en) Germicidal and fungicidal compositions
BR9908533A (pt) Revestimento de biocompatibilidade melhorada para implantes médicos e dispositivos médicos de exposição aguda, processo para produção de um revestimento de biocompatibilidade melhorada, e, implante médico ou dispositivo médico de exposição aguda
TH58451B (th) อีโพรซาร์แทน ไดไฮเดรท และกรรมวิธีสำหรับการผลิตและสูตรผสม
TH18762A (th) กรรมวิธีสำหรับเตรียมเกลือไอเซไธโอเนทเอสเทอร์
NO942723L (no) Anvendelse av vanndige lösninger som inneholder peroksodisulfationer til behandling av ondartede celler
TH13949EX (th) วิธีการเตรียมยารับประทานซึ่งถูกเคลือบเพื่อให้ละลายในลำไส้ซึ่งมีสารประกอบที่ไม่เสถียรในกรด
KR950013510A (ko) 산불안정화합물의 경구용 약제와 그 제조방법.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time